Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special Meeting

2026-03-01 00:05:45

Abstract generation in progress

Karyopharm Therapeutics (NASDAQ:KPTI) shareholders have approved a plan to nearly double the company’s total authorized shares from 58,333,333 to 111,000,000, and common shares from 53,333,333 to 106,000,000. This decision was made at a virtual special meeting held on February 18, 2026, and also included approval of a contingency adjournment to solicit additional proxies if needed. Final vote results are pending disclosure in a Form 8-K.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.